[go: up one dir, main page]

CL2019000304A1 - Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento. - Google Patents

Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.

Info

Publication number
CL2019000304A1
CL2019000304A1 CL2019000304A CL2019000304A CL2019000304A1 CL 2019000304 A1 CL2019000304 A1 CL 2019000304A1 CL 2019000304 A CL2019000304 A CL 2019000304A CL 2019000304 A CL2019000304 A CL 2019000304A CL 2019000304 A1 CL2019000304 A1 CL 2019000304A1
Authority
CL
Chile
Prior art keywords
aging
treatment
blood plasma
plasma fractions
treatments related
Prior art date
Application number
CL2019000304A
Other languages
English (en)
Inventor
David Bell
Karoly Nikolich
Vu Dang
Steven P Braithwaite
Ian Gallager
S Sakura Minami
Joe Mccracken
Original Assignee
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkahest Inc filed Critical Alkahest Inc
Publication of CL2019000304A1 publication Critical patent/CL2019000304A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

SE DESCRIBEN MÉTODOS Y COMPOSICIONES PARA EL TRATAMIENTO Y/O PREVENCIÓN DE AFECCIONES RELACIONADAS CON EL ENVEJECIMIENTO. LAS COMPOSICIONES UTILIZADAS EN LOS MÉTODOS INCLUYEN FRACCIONES DERIVADAS DE PLASMA SANGUÍNEO CON EFICACIA PARA TRATAR Y/O PREVENIR AFECCIONES RELACIONADAS CON EL ENVEJECIMIENTO, TAL COMO TRASTORNOS NEUROCOGNITIVOS.
CL2019000304A 2016-08-18 2019-02-05 Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento. CL2019000304A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662376529P 2016-08-18 2016-08-18
US201662412258P 2016-10-24 2016-10-24

Publications (1)

Publication Number Publication Date
CL2019000304A1 true CL2019000304A1 (es) 2019-05-31

Family

ID=61196950

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000304A CL2019000304A1 (es) 2016-08-18 2019-02-05 Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.

Country Status (30)

Country Link
US (2) US20190321449A1 (es)
EP (2) EP3995140A1 (es)
JP (3) JP7316931B2 (es)
KR (3) KR20240036720A (es)
CN (2) CN115957309A (es)
AU (4) AU2017312722B2 (es)
BR (1) BR112019003172A2 (es)
CA (1) CA3033051A1 (es)
CL (1) CL2019000304A1 (es)
CY (1) CY1124695T1 (es)
DK (1) DK3484502T3 (es)
ES (1) ES2899147T3 (es)
HR (1) HRP20211628T1 (es)
HU (1) HUE056294T2 (es)
IL (2) IL264660B2 (es)
LT (1) LT3484502T (es)
MA (1) MA45692B1 (es)
MD (1) MD3484502T2 (es)
MX (2) MX2019001718A (es)
MY (1) MY202968A (es)
NZ (1) NZ750885A (es)
PL (1) PL3484502T3 (es)
PT (1) PT3484502T (es)
RS (1) RS62558B1 (es)
SG (1) SG11201901273TA (es)
SI (1) SI3484502T1 (es)
SM (1) SMT202100666T1 (es)
UA (1) UA126232C2 (es)
WO (1) WO2018034712A1 (es)
ZA (1) ZA202004834B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018200560A1 (en) * 2017-04-26 2018-11-01 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
WO2019222265A1 (en) 2018-05-15 2019-11-21 Alkahest, Inc. Treatment of aging-associated disease with modulators of leukotriene a4 hydrolase
CN110787187B (zh) * 2018-07-16 2022-05-13 北京豪思生物科技股份有限公司 一种增强记忆力和提高认知功能的血浆混合物及其制备方法和应用
CN110724176B (zh) * 2018-07-16 2021-10-26 北京豪思生物科技有限公司 一种治疗阿尔茨海默症的血浆蛋白分离物及其制备方法和应用
MX2021000707A (es) * 2018-07-20 2021-03-25 Alkahest Inc Regimen de dosificacion para el tratamiento de deterioros cognitivos y motores con plasma de sangre y productos de plasma de sangre.
SG11202103696XA (en) 2018-10-26 2021-05-28 Alkahest Inc Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery
CN110448686B (zh) * 2019-09-19 2022-11-04 北京豪思生物科技股份有限公司 铜蓝蛋白联合运铁蛋白的应用
US20220362293A1 (en) * 2019-09-25 2022-11-17 Cytegen Corp. Treatment of Mitochondrial Deficits and Age-Related Diseases Using Blood Products
EP4054597A4 (en) 2019-11-04 2024-02-21 Alkahest, Inc. Blood plasma fractions for use in muscle regeneration
US11484551B2 (en) 2019-11-20 2022-11-01 Alkahest, Inc. Method of treating liver failure with plasma fraction IV-4
WO2021102032A1 (en) 2019-11-20 2021-05-27 Alkahest, Inc. Blood plasma fractions for use in liver regeneration
US20220233587A1 (en) * 2021-01-06 2022-07-28 Yuvan Research, Inc. Anti-aging compositions and uses thereof
WO2023076679A1 (en) 2021-11-01 2023-05-04 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases
AU2023378813A1 (en) * 2022-11-11 2025-05-29 Alkahest, Inc. Blood plasma fractions for improvement of myelination
WO2024258622A1 (en) * 2023-06-13 2024-12-19 Alkahest, Inc. Blood plasma fractions as a treatment for chemotherapy induced cognitive disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869431A (en) 1973-03-12 1975-03-04 Firestone Tire & Rubber Co Polyamides and their production
US4624780A (en) 1982-06-28 1986-11-25 Alpha Therapeutic Corporation Fractionation of blood plasma
DE3612137A1 (de) * 1986-04-10 1987-10-15 Biotest Pharma Gmbh Steriles plasmaaustauschmittel
US5138034A (en) * 1989-07-12 1992-08-11 The Green Cross Corporation Method of fractionating plasma proteins
US5110907A (en) 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5219995A (en) 1992-07-14 1993-06-15 Alpha Therapeutic Corporation Plasma fraction purification
US5561115A (en) * 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
EP1393740A4 (en) * 2001-05-11 2005-08-10 Juridical Foundation NEW MEANS FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
WO2004056318A2 (en) * 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
US20040146565A1 (en) * 2003-01-28 2004-07-29 Lauridsen Group Incorporated First lipoprotein fraction and therapeutic compositions of same
US20130121979A1 (en) * 2003-12-29 2013-05-16 Allan Mishra Method of treating cancer using platelet compositions
ES2257225B1 (es) 2006-02-17 2007-03-16 Grifols, S.A Preparacion terapeutica de fviia de muy alta pureza y metodo para su obtencion.
ES2332846B1 (es) * 2007-10-26 2010-07-08 Grifols, S.A. Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
ES2294976B1 (es) * 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".
PT2271382E (pt) 2008-04-15 2013-05-07 Grifols Therapeutics Inc Ultrafiltração em dois andares/diafiltração
US20090297485A1 (en) * 2008-05-28 2009-12-03 Allan Mishra Compositions and methods for treating psychiatric and neurodegenerative disorders
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
WO2014182631A1 (en) * 2013-05-06 2014-11-13 Baxter International Inc. Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g
MX2016007492A (es) 2013-12-09 2017-03-06 Univ Leland Stanford Junior Métodos y composiciones para el tratamiento de afecciones asociadas con el envejecimiento.
ES2524516B1 (es) 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
EA039316B1 (ru) * 2016-10-24 2022-01-12 Алкахест, Инк. Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
US11040068B2 (en) * 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
WO2018200560A1 (en) * 2017-04-26 2018-11-01 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products

Also Published As

Publication number Publication date
AU2017312722A1 (en) 2019-03-14
KR20190032614A (ko) 2019-03-27
JP7316931B2 (ja) 2023-07-28
UA126232C2 (uk) 2022-09-07
SI3484502T1 (sl) 2022-01-31
KR20220107322A (ko) 2022-08-02
PT3484502T (pt) 2021-11-18
BR112019003172A2 (pt) 2019-05-28
JP2019528269A (ja) 2019-10-10
HRP20211628T1 (hr) 2022-02-04
AU2021240142B2 (en) 2024-06-20
RS62558B1 (sr) 2021-12-31
IL264660A (es) 2019-04-30
AU2024219765A1 (en) 2024-10-10
ES2899147T3 (es) 2022-03-10
LT3484502T (lt) 2021-12-10
HUE056294T2 (hu) 2022-02-28
MX2019001718A (es) 2019-09-13
EP3484502A4 (en) 2020-03-04
JP7447069B2 (ja) 2024-03-11
AU2020200181B2 (en) 2021-07-22
SG11201901273TA (en) 2019-03-28
IL264660B1 (en) 2023-11-01
EP3995140A1 (en) 2022-05-11
PL3484502T3 (pl) 2022-01-31
MY202968A (en) 2024-05-31
NZ750885A (en) 2021-07-30
US20190321449A1 (en) 2019-10-24
ZA202004834B (en) 2022-07-27
DK3484502T3 (da) 2021-10-25
AU2021240142A1 (en) 2021-10-28
AU2020200181A1 (en) 2020-01-30
EP3484502A1 (en) 2019-05-22
US20220152161A1 (en) 2022-05-19
MA45692B1 (fr) 2021-10-29
AU2017312722B2 (en) 2020-01-02
MX2024008963A (es) 2024-07-30
JP2023156459A (ja) 2023-10-24
EP3484502B1 (en) 2021-08-25
CN115957309A (zh) 2023-04-14
MA45692A (fr) 2019-05-22
KR20240036720A (ko) 2024-03-20
CN109963582A (zh) 2019-07-02
SMT202100666T1 (it) 2022-01-10
CY1124695T1 (el) 2022-07-22
IL304946A (en) 2023-10-01
MD3484502T2 (ro) 2022-01-31
WO2018034712A1 (en) 2018-02-22
JP2022037124A (ja) 2022-03-08
CA3033051A1 (en) 2018-02-22
CN109963582B (zh) 2022-12-27
IL264660B2 (en) 2024-03-01

Similar Documents

Publication Publication Date Title
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2018003213A1 (es) Inhibidores enzimáticos.
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
DOP2017000048A (es) Compuestos aminopirimidinilo como inhibidores de jak.
EP3735976A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
EA201990257A1 (ru) Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
CO2018008846A2 (es) Derivados de carboxamida útiles como inhibidores de rsk
GT201500294A (es) Compuestos de biaril-amida como inhibidores de cinasa
NI201600071A (es) Compuestos de inhibidor de autotaxina
DOP2016000194A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CR20160200A (es) Combinaciones de inhibidores de histona desacetilasa y fármacos inmunomoduladores
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
CR20170187A (es) 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
MX386860B (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
MX2023012640A (es) Uso de profarmacos de riluzol para tratar ataxias.
MX394452B (es) Inhibicion de la actividad de olig2.
MX2021000542A (es) Apirasas solubilizadas, metodos y usos.
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.